F16.980 Hallucinogen use, unspecified with hallucinogen-induced anxiety disorder

Name of the Condition

• Hallucinogen Use, Unspecified with Hallucinogen-Induced Anxiety Disorder
• Medical Term: ICD-10-CM F16.980

Summary

Hallucinogen use, unspecified with hallucinogen-induced anxiety disorder refers to the use of hallucinogenic substances associated with a clinically recognized anxiety disorder induced by these substances, where the specific pattern of use is not detailed. This code is applied when documentation confirms hallucinogen exposure and an associated anxiety disorder, but does not specify abuse, dependence, or intoxication. It is used for cases where a hallucinogen-induced anxiety disorder is present without further classification of the use pattern.

Causes

Hallucinogen use, unspecified with hallucinogen-induced anxiety disorder typically involves substances that alter perception, mood, or cognitive function, such as LSD, psilocybin, or mescaline. The induced anxiety disorder arises from the physiological or psychological effects of these substances, though the documentation does not specify a problematic pattern beyond the associated condition. Psychological factors like curiosity or social influences may contribute to initiation, but the focus is on the resulting anxiety disorder.

Risk Factors

• Recreational or experimental use of hallucinogens
• Pre-existing mental health conditions
• Genetic predisposition to substance use disorders
• Social or peer pressure to use drugs
• Access to hallucinogenic substances

Symptoms

• Persistent anxiety, fear, or panic
• Restlessness or agitation
• Excessive worry or rumination
• Physical symptoms of anxiety (e.g., rapid heartbeat, sweating, trembling)
• Avoidance of situations or stimuli associated with hallucinogen use

Diagnosis

Diagnosis requires clinical documentation of hallucinogen use and a hallucinogen-induced anxiety disorder. Healthcare providers assess symptoms, substance use history, and rule out other causes of anxiety. The pattern of use is not specified, but the presence of an anxiety disorder linked to hallucinogen exposure is confirmed. No additional criteria for abuse, dependence, or intoxication are required for this code.

Treatment Options

Treatment focuses on managing anxiety symptoms and addressing substance use. Options may include psychotherapy (e.g., cognitive-behavioral therapy), anxiety-reducing medications, and support for reducing or discontinuing hallucinogen use. Individualized plans consider the severity of symptoms and patient needs.

Prognosis and Follow-Up

Prognosis depends on the duration and severity of anxiety symptoms, as well as the frequency of hallucinogen use. With appropriate treatment, many individuals experience symptom reduction. Follow-up care may involve monitoring for recurrence of anxiety or substance use, and adjusting interventions as needed.

Complications

• Worsening of anxiety symptoms
• Increased risk of substance use disorders
• Impaired daily functioning (e.g., work, relationships)
• Co-occurring mental health conditions (e.g., depression)

Lifestyle & Prevention

• Avoiding hallucinogenic substances to prevent symptom recurrence
• Practicing stress-reduction techniques (e.g., mindfulness, exercise)
• Seeking support from mental health professionals or support groups
• Educating oneself about the risks of hallucinogen use

When to Seek Professional Help

Seek help if anxiety symptoms persist, worsen, or interfere with daily life. Also, consult a healthcare provider if hallucinogen use continues despite negative consequences or if there is concern about substance use patterns.

Tips for Medical Coders

Use this code when documentation confirms hallucinogen use and a hallucinogen-induced anxiety disorder, without specifying the pattern of use (e.g., abuse, dependence). Ensure the anxiety disorder is directly linked to hallucinogen exposure. Do not use this code if the anxiety disorder is due to another cause or if more specific use patterns (e.g., intoxication) are documented.